. Aducanumab anti-amyloid immunotherapy induces sustained microglial and immune alterations. J Exp Med. 2024 Feb 5;221(2) Epub 2024 Jan 16 PubMed.

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

Therapeutics

  1. Aduhelm

News

  1. Donanemab Approval Likely to Pose New Quandaries for Clinicians